FLEBODIA 600

Active material: Diosmin
When ATH: C05CA03
CCF: Venous drug
ICD-10 codes (testimony): I83, I84, I87.2
When CSF: 01.15.01.01
Manufacturer: Laboratories INNOTHERA (France)

PHARMACEUTICAL FORM, COMPOSITION AND PACKAGING

Pills, coated Pink colour, round, lenticular; of presentations – the core of greyish-brown.

Excipients: talc, colloidal silicon dioxide, stearic acid, microcrystalline cellulose, protective film type Sepifilm 002 (gipromelloza, microcrystalline cellulose, poliэtilenglikoly stearate 400), type dye mixture Sepisperse AP 5523 (propylene glycol, gipromelloza, Titanium dioxide, cochineal red (Ponceau 4R), iron oxide black, iron oxide red), Opaglos 6000 (the wax palm, beeswax, gummilak, ethanol 95%) in an amount, necessary for one tablet, coated.

15 PC. – blisters (1) – packs cardboard.
15 PC. – blisters (2) – packs cardboard.

Pharmacological action

Preparation, used in violation of venous circulation. It has venotonic (decreases venous distensibility, increases their tone / dose-effect /, reduces venous stasis), improves lymphatic drainage (improves skin tone and reduce the frequency of lymph capillaries, their functional density increases, reduces the lymphatic pressure), improves microcirculation (increases capillary resistance / dose-effect /, reduces their permeability), It reduces the adhesion of leukocytes to the venous wall and their migration to tissues paravenoznye, It improves oxygen diffusion and perfusion in the skin tissue, It has anti-inflammatory action. Enhances the vasoconstrictor effect of epinephrine (adrenaline), norepinephrine (noradrenaline), blocks the production of free radicals, prostaglandins and thromboxane.

Pharmacokinetics

Absorption

Rapidly absorbed from the gastrointestinal tract, detected in plasma after 2 h after administration. FROM_max plasma levels achieved after 5 h after administration.

Distribution

Evenly distributed and accumulated in all layers of the wall of the hollow veins and subcutaneous veins of the lower extremities, less – in the veins of the kidneys, liver, lung and other tissues. Selective accumulation of diosmin and / or its metabolites in venous vessels reaches through 9 hours after administration and persists for 96 no.

Deduction

Excreted in the urine – 79%, with feces – 11%, the bile - 2.4%.

Testimony

- Varicose veins;

- Chronic insufficiency of the lower limbs lymphovenous;

- Hemorrhoids;

- Violations of the microcirculation.

Dosage regimen

At varicose veins in the early stage of chronic disease lymphovenous (heaviness in the legs) appoint 1 tab. / day in the morning before breakfast for 2 Months, at severe chronic disease lymphovenous (swelling, pain, convulsions) – Treatment continued for 3-4 Months, in the presence of trophic changes and ulcers – 6 months or more. Repeat the treatment after 2-3 Months.

At aggravation of hemorrhoids appoint 2-3 tab. / day during a meal for 7 days, Further, if necessary, can be extended for reception 1 tab. 1 times / day for 1-2 Months.

At lymphovenous treatment of chronic failure in II and III trimesters of pregnancy appoint 1 tab. 1 time / day and cancel for 2-3 weeks before delivery. When you miss one or more methods should continue to use the drug in normal dosage.

Side effect

From the digestive system: dyspepsia.

CNS: headache.

Other: rarely – allergic reactions (requiring treatment interruption), associated with hypersensitivity to the drug.

Contraindications

- Childhood and adolescence up 18 years;

- Hypersensitivity to the drug.

Pregnancy and lactation

Until now, in clinical practice there were no reports of any side effects when using the drug in pregnant women.

During breast-feeding is not recommended taking the drug, tk. There are no data on the penetration of the drug in breast milk.

IN experimental studies There were no teratogenic effects of the drug on the fetus.

Cautions

Treatment of acute attacks of hemorrhoids is carried out in combination with other drugs, in the absence of a rapid clinical effect needs further study and adjust the therapy.

There is evidence of potential efficacy in the treatment of placental insufficiency, for the prevention of bleeding, arising from the use of an intrauterine device, and in the period after phlebectomy.

Overdose

Symptoms of overdose Flebodia 600 not disclosed.

Drug Interactions

Clinically significant drug interactions drug Flebodia 600 with other drugs is not established.

Conditions of supply of pharmacies

The drug is released under the prescription.

Conditions and terms

The drug should be stored out of reach of children at or above 30 ° C. Shelf life – 2 year.